Robert W. Baird restated their hold rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a report released on Friday morning. Robert W. Baird currently has a $120.00 price target on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Cann reissued a buy rating and issued a $199.00 price target on shares of TESARO in a report on Friday, September 8th. SunTrust Banks, Inc. reissued a buy rating and issued a $235.00 price target on shares of TESARO in a report on Sunday, August 20th. Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the company a buy rating in a report on Wednesday, July 19th. Citigroup Inc. reissued a buy rating and issued a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $199.00 target price on shares of TESARO in a report on Sunday, September 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. TESARO currently has a consensus rating of Hold and a consensus target price of $161.72.

Shares of TESARO (NASDAQ:TSRO) opened at $91.09 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO has a fifty-two week low of $89.00 and a fifty-two week high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) earnings per share. equities analysts expect that TESARO will post -8.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/tesaro-inc-tsro-earns-hold-rating-from-robert-w-baird.html.

In other news, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Martin H. Jr. Huber sold 592 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares in the company, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock worth $4,628,976 over the last 90 days. 34.60% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TSRO. Exane Derivatives acquired a new position in TESARO in the 3rd quarter valued at about $106,000. Botty Investors LLC acquired a new position in TESARO in the 2nd quarter valued at about $140,000. Nordea Investment Management AB acquired a new position in TESARO in the 2nd quarter valued at about $167,000. Oppenheimer Asset Management Inc. grew its stake in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.